@teamoncology @JavierCortesMD @antoniollombar1 @BianchiniGP Indeed, remind me to not ask @BianchiniGP to examine any of my PhD students 🤯
English
Tim Robinson
652 posts
Tim Robinson
@drtimrobinson
Cons Senior Lecturer Med Onc UoB. Breast oncology, TNBC, genetics, biomarkers. Quality of life!
Bristol, England Katılım Kasım 2019
441 Takip Edilen397 Takipçiler
We had a great discussion.
@JavierCortesMD
@teamoncology
@antoniollombar1
@BianchiniGP
@drtimrobinson
Gil Morgan, MD@weoncologists
FREE EVENT IN SAN ANTONIO TODAY MEDiscussion during #SABCS25 DEC 10, 2025 FREE REGISTRATION ⭐️REGISTER HERE👉buff.ly/DML25ud A Great opportunity to interact with an amazing faculty @JavierCortesMD @teamoncology @antoniollombar1 @BianchiniGP @drtimrobinson
English
Tim Robinson retweetledi
FREE EVENT IN SAN ANTONIO TODAY
MEDiscussion during #SABCS25
DEC 10, 2025 FREE REGISTRATION
⭐️REGISTER HERE👉buff.ly/DML25ud
A Great opportunity to interact with an amazing faculty
@JavierCortesMD
@teamoncology
@antoniollombar1
@BianchiniGP
@drtimrobinson
OncoAlert@OncoAlert
DEAR COLLEAGUES IN SAN ANTONIO A Special invitation to JOIN US LIVE at MEDiscussion during #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 buff.ly/DML25ud Tomorrow DEC 10, 2025 FREE REGISTRATION 🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno 🗣 Moderator: Dr. Giampaolo Bianchini 💬 Discussants: Dr. Pérez-García, Dr. Bartsch, Dr. Robinson Don’t miss this dynamic, multi-expert dialogue shaping the future of breast cancer care. @JavierCortesMD @teamoncology @antoniollombar1 @BianchiniGP @drtimrobinson
English
Tim Robinson retweetledi
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 buff.ly/qC8Poj0
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
💬 Discussants: Dr. Pérez-García, Dr. Bartsch, Dr. Robinson
Don’t miss this dynamic, multi-expert dialogue shaping the future of breast cancer care.
@JavierCortesMD
@teamoncology
@antoniollombar1
@BianchiniGP
@drtimrobinson
@wearemedsir
English
@ErikaHamilton9 A lot of abstracts but not a lot of payloads!
English
LARVOL@Larvol
A look at ADC trials in Breast Cancer to be presented at @myESMO 2025. Explore more insights and data from #ESMO25: t.ly/yDvnj #LARVOL #BreastCancer #CancerResearch #CancerData #Oncology #OncologyInsights #ADCs #ClinicalTrials #MedicalOncology | @PTarantinoMD | @dr_yakupergun | @ErikaHamilton9 | @MamMa_mimumemo | @kazuki_nozawa | @drsarahsam | @SuyogCancer
English
This is reassuring data. We must get better at managing HFS though!
Erika Hamilton, MD, FASCO@ErikaHamilton9
Practice affirming. Adjuvant capecitabine for residual disease after adjuvant chemo improves outcomes. Reassuring this is true in a real world data set and not just the CREATE-X trial. Interestingly only half receive adjuvant therapy. #bcsm #TNBC esmoopen.com/article/S2059-…
English
@JiaJennyLiu @oncocook @JCO_ASCO @Starpharma_ASX @ECMC_UK @NECTANSW Please do, I know the team at the Christie well!
English
@drtimrobinson @oncocook @JCO_ASCO @Starpharma_ASX @ECMC_UK @NECTANSW There are ongoing discussions with sponsor @Starpharma_ASX for further studies in specific tumor types. If interested will put you in touch!
English
Great tweetorial from @JiaJennyLiu on our newly published study in @JCO_ASCO using technology developed by @Starpharma_ASX. Delivered with @ECMC_UK and @NECTANSW
Jia (Jenny) Liu MD PhD@JiaJennyLiu
Our early-phase trial of DEP-SN38, a poly-lysine dendrimer–conjugated SN38 platform, is now published via @JCO_ASCO! @oncocook 💡As TOP1 inhibitor ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies. Can dendrimers assist? ⬇️🧵
English
@JAMouabbi @Sonyareid07 Agreed, I saw this and found it sobering. We must do better
English
A lot of exciting data came out of #ASCO25—but some presentations were a sobering wake-up call.
As @Sonyareid07 highlighted, nearly 50% of patients with mTNBC don’t receive any treatment beyond first-line therapy.
This is unacceptable. In 2025, this should not be the reality. It should alarm every oncologist.
Our patients deserve better—we must innovate, advocate, and push for access to more effective therapies.
#bcsm #mTNBC
English
@BreastDocUK Reassuring data for those on aromatase
Inhibitors
English
Yet another reassuring data point that vaginal estrogens are safe after #breastcancer
800 women all over 65 compared to 17820 with no vaginal estrogen
No survival detriment (a benefit possibly due to survivor bias)
#ASCO25
English
Tim Robinson retweetledi
Insomnia has a huge impact on physical & mental health & even more so if you are living with secondary breast cancer. On #WorldSleepDay we're asking patients to complete our research project survey with @UniStrathclyde in tailored insomnia interventions: tinyurl.com/2f695u59
English
@stolaney1 @antgiorda @RebeccaDSing @SABCSSanAntonio @DFCI_BreastOnc @OncoAlert A lot of interesting questions remain…
English
Excellent poster discussion by @antgiorda including discussion of OS subgroup data from KN522 (poster by @RebeccaDSing )
@SABCSSanAntonio #SABCS24 @DFCI_BreastOnc @OncoAlert
English
@PTarantinoMD Nice data paolo. Are you able to tell us what the median pfs on tdxd was as first ADC?
English
@MelissaFrizzie1 @MGMcNamara @ncukcharity @UKINETS @TheChristieNHS @MCRCnews @CRUK_MI @FlorentMouliere @cruk_nbc Congrats!
English
@MGMcNamara @ncukcharity @UKINETS @TheChristieNHS @MCRCnews @CRUK_MI Thanks @MGMcNamara! Thanks to @ncukcharity and @UKINETS for supporting our new exciting project! This will be a great team effort that I will co-lead with Dr Alexandra Clipson and @FlorentMouliere @cruk_nbc
English
Well done to @MelissaFrizzie1 on receiving @ncukcharity 24 pump priming grant; cfDNA methylation profiling for detection & classification of well diff NET, carrying on PhD work on PD-NEC @UKINETS @TheChristieNHS @MCRCnews @CRUK_MI
English
🧵 SBRT in Oligometastatic Breast Cancer: What does the evidence show? A summary of key studies and their impact on survival. Let’s dive in! 👇
1/ What is Oligometastatic Breast Cancer (OMBC)?
OMBC is an intermediate state between localized and widespread metastatic disease, characterized by limited metastases (typically ≤5). It’s a promising target for local therapies like SBRT (Stereotactic Body Radiotherapy).
English
@oncology_bg @SuyogCancer @darioT_ @DrMarkLythgoe @Nature @BreastDocUK @BreastCancerNow @ElisaAgostinett @SullivanProf We also shouldn’t forget in this context fulvestrant injections are not without therapeutic burden. Most patients hate them!
English
@SuyogCancer @darioT_ @DrMarkLythgoe @drtimrobinson @Nature @BreastDocUK @BreastCancerNow @ElisaAgostinett @SullivanProf That’s why we shouldn’t frame these results “only” in the context of cost savings. Cost savings is great but it also saves patients from other toxicities and longer time with therapeutic burden.
English
Hugely interesting paper in @nature about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?
@darioT_ @BreastDocUK @SuyogCancer @oncology_bg @BreastCancerNow @ElisaAgostinett @SullivanProf
nature.com/articles/s4158…
English
@saadvikdr @OncoAlert @dr_yakupergun @SuyogCancer Really really needs stratifying by pCR status: delta was 0.4% with a pathCR but toxicity I’m sure was experience by all. Trial design doesn’t allow us to unpick this. We need better trial designs!
We published on this topic recently
ascopubs.org/doi/abs/10.120…
English
Keynote 522, shows OS advantage at median follow up of 75months. Delta of 5% with use of Pembrolizumab with chemotherapy for early TNBC.
@dr_yakupergun @SuyogCancer @OncoAlert #MedX
ascopost.com/issues/decembe…
English
Tim Robinson retweetledi
Cross-ancestral GWAS identifies 29 novel variants across Head and Neck Cancer subsites medrxiv.org/cgi/content/sh… #medRxiv
English
Tim Robinson retweetledi
🆕 opportunity!
🧑⚕️Interested in novel IO & cell therapy in solid cancer? Keen to gain experience in early phase trials?
Come join Fiona, me & our amazing team as a ‘Clinical Fellow in Advanced Immunotherapy & Cell Therapy Team’.
Deadline 27 Nov 2024 👇
healthjobsuk.com/job/v6778827
English